Literature DB >> 12524400

Missing endomysial and reticulin binding of coeliac antibodies in transglutaminase 2 knockout tissues.

I R Korponay-Szabó1, K Laurila, Z Szondy, T Halttunen, Z Szalai, I Dahlbom, I Rantala, J B Kovács, L Fésüs, M Mäki.   

Abstract

BACKGROUND: Autoantibodies against transglutaminase 2 (TG2) are thought to be responsible for the endomysial (EMA), reticulin (ARA), and jejunal antibody (JEA) tissue binding of serum samples from coeliac patients but the exclusive role of TG2 in these staining patterns has not yet been established. AIMS: To evaluate whether antigens other than TG2 contribute to EMA/ARA/JEA reactions. PATIENTS: Serum samples from 61 EMA/ARA/JEA positive untreated patients with coeliac disease, 40 dermatitis herpetiformis patients, and 34 EMA/ARA/JEA negative non-coeliac controls were tested.
METHODS: TG2 knockout (TG2-/-) and wild-type mouse oesophagus, jejunum, liver, and kidney sections, and TG2-/- sections coated with human recombinant TG2 were used as substrates in single and double immunofluorescent studies for patient IgA binding and tissue localisation of TG2, fibronectin, actin, and calreticulin.
RESULTS: None of the patient serum samples elicited EMA, ARA, or JEA binding in TG2-/- morphologically normal tissues. In contrast, 96 of 101 gluten sensitive patient samples (95%) reacted with wild-type mouse tissues and all 101 reacted in EMA/ARA/JEA patterns with TG2-/- mouse tissues coated with human TG2. Serum IgA binding to TG2-/- smooth muscle cells was observed in low titres in 31.1%, 27.5%, and 20.5%, and to TG2-/- epithelium in 26.3%, 5.0%, and 8.8% of coeliac, dermatitis herpetiformis, and control samples, respectively. These positivities partly colocalised with actin and calreticulin but not with TG2 or fibronectin.
CONCLUSIONS: EMA/ARA/JEA antibody binding patterns are exclusively TG2 dependent both in coeliac and dermatitis herpetiformis patients. Actin antibodies are responsible for some positivities which are not part of the EMA/ARA/JEA reactions.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12524400      PMCID: PMC1774982          DOI: 10.1136/gut.52.2.199

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  22 in total

1.  Antibody reactivity against human and guinea pig tissue transglutaminase in children with celiac disease.

Authors:  T Hansson; I Dahlbom; J Hall; A Holtz; L Elfman; A Dannaeus; L Klareskog
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-04       Impact factor: 2.839

2.  Increased levels of IgA antibodies against desmin in children with coeliac disease.

Authors:  K Teesalu; O Uibo; N Kalkkinen; P Janmey; R Uibo
Journal:  Int Arch Allergy Immunol       Date:  2001-10       Impact factor: 2.749

3.  Anti-tissue transglutaminase, anti-endomysium and anti-R1-reticulin autoantibodies-the antibody trinity of coeliac disease.

Authors:  R J Lock; J E Gilmour; D J Unsworth
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  Evolution of transglutaminase genes: identification of a transglutaminase gene cluster on human chromosome 15q15. Structure of the gene encoding transglutaminase X and a novel gene family member, transglutaminase Z.

Authors:  P Grenard; M K Bates; D Aeschlimann
Journal:  J Biol Chem       Date:  2001-06-04       Impact factor: 5.157

5.  Tissue transglutaminase is the target in both rodent and primate tissues for celiac disease-specific autoantibodies.

Authors:  I R Korponay-Szabó; S Sulkanen; T Halttunen; F Maurano; M Rossi; G Mazzarella; K Laurila; R Troncone; M Mäki
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-11       Impact factor: 2.839

6.  Comparative evaluation of serologic tests for celiac disease: a European initiative toward standardization.

Authors:  M Stern
Journal:  J Pediatr Gastroenterol Nutr       Date:  2000-11       Impact factor: 2.839

7.  Evidence for existence of coeliac disease autoantigens apart from tissue transglutaminase.

Authors:  H H Uhlig; J Lichtenfeld; A A Osman; T Richter; T Mothes
Journal:  Eur J Gastroenterol Hepatol       Date:  2000-09       Impact factor: 2.566

8.  Analysis of epidermal-type transglutaminase (TGase 3) expression in mouse tissues and cell lines.

Authors:  K Hitomi; Y Horio; K Ikura; K Yamanishi; M Maki
Journal:  Int J Biochem Cell Biol       Date:  2001-05       Impact factor: 5.085

9.  Gene disruption of tissue transglutaminase.

Authors:  V De Laurenzi; G Melino
Journal:  Mol Cell Biol       Date:  2001-01       Impact factor: 4.272

10.  Epidermal transglutaminase (TGase 3) is the autoantigen of dermatitis herpetiformis.

Authors:  Miklós Sárdy; Sarolta Kárpáti; Barbara Merkl; Mats Paulsson; Neil Smyth
Journal:  J Exp Med       Date:  2002-03-18       Impact factor: 14.307

View more
  16 in total

Review 1.  Antibodies in celiac disease: implications beyond diagnostics.

Authors:  Sergio Caja; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  Cell Mol Immunol       Date:  2011-01-31       Impact factor: 11.530

2.  Endomysial antibody-negative coeliac disease: clinical characteristics and intestinal autoantibody deposits.

Authors:  T T Salmi; P Collin; I R Korponay-Szabó; K Laurila; J Partanen; H Huhtala; R Király; L Lorand; T Reunala; M Mäki; K Kaukinen
Journal:  Gut       Date:  2006-03-29       Impact factor: 23.059

3.  In vivo targeting of intestinal and extraintestinal transglutaminase 2 by coeliac autoantibodies.

Authors:  I R Korponay-Szabó; T Halttunen; Z Szalai; K Laurila; R Király; J B Kovács; L Fésüs; M Mäki
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

4.  Coeliac disease-specific autoantibodies targeted against transglutaminase 2 disturb angiogenesis.

Authors:  E Myrsky; K Kaukinen; M Syrjänen; I R Korponay-Szabó; M Mäki; K Lindfors
Journal:  Clin Exp Immunol       Date:  2008-02-14       Impact factor: 4.330

5.  Elevated serum anti-Saccharomyces cerevisiae, anti-I2 and anti-OmpW antibody levels in patients with suspicion of celiac disease.

Authors:  Sara Ashorn; Hanna Raukola; Tuuli Välineva; Merja Ashorn; Bo Wei; Jonathan Braun; Immo Rantala; Katri Kaukinen; Tiina Luukkaala; Pekka Collin; Markku Mäki; Sari Iltanen
Journal:  J Clin Immunol       Date:  2008-05-22       Impact factor: 8.317

6.  Celiac disease IgA modulates vascular permeability in vitro through the activity of transglutaminase 2 and RhoA.

Authors:  Essi Myrsky; Sergio Caja; Zsofi Simon-Vecsei; Ilma R Korponay-Szabo; Cristina Nadalutti; Russell Collighan; Alexandre Mongeot; Martin Griffin; Markku Mäki; Katri Kaukinen; Katri Lindfors
Journal:  Cell Mol Life Sci       Date:  2009-08-13       Impact factor: 9.261

Review 7.  Transglutaminase 2 inhibitors and their therapeutic role in disease states.

Authors:  Matthew Siegel; Chaitan Khosla
Journal:  Pharmacol Ther       Date:  2007-05-13       Impact factor: 12.310

8.  Injection of celiac disease patient sera or immunoglobulins to mice reproduces a condition mimicking early developing celiac disease.

Authors:  Suvi Kalliokoski; Sergio Caja; Rafael Frias; Kaija Laurila; Outi Koskinen; Onni Niemelä; Markku Mäki; Katri Kaukinen; Ilma R Korponay-Szabó; Katri Lindfors
Journal:  J Mol Med (Berl)       Date:  2014-09-12       Impact factor: 4.599

9.  Extracellular transglutaminase 2 is catalytically inactive, but is transiently activated upon tissue injury.

Authors:  Matthew Siegel; Pavel Strnad; R Edward Watts; Kihang Choi; Bana Jabri; M Bishr Omary; Chaitan Khosla
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

10.  Transglutaminase 2-specific autoantibodies in celiac disease target clustered, N-terminal epitopes not displayed on the surface of cells.

Authors:  Rasmus Iversen; Roberto Di Niro; Jorunn Stamnaes; Knut E A Lundin; Patrick C Wilson; Ludvig M Sollid
Journal:  J Immunol       Date:  2013-05-20       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.